Assessing TLS Risk in Patients Receiving Anticancer Treatment for Lymphoma or Leukemia Use this tool to evaluate your patients’ risk for tumor lysis syndrome (TLS) to help guide management decisions. STEP 1: CANCER TYPE STEP 2: LAB VALUES RISK ASSESSMENT STEP 1 Select the relevant leukemia or lymphoma cancer type 1 Select Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML) Burkitt lymphoma (BL) Chronic lymphocytic leukemia (CLL) Chronic myeloid leukemia (CML) Diffuse large B-cell lymphoma (DLBCL
There will be a maximum of 4 selections to make.
Patients with low-risk disease can become intermediate-risk for TLS when renal dysfunction and/or renal involvement is present